Real-world individual patient-level analysis for mavacamten in obstructive hypertrophic cardiomyopathy: multi-domain response, safety and cyp2c19 genotype effects

11 May 2026 (13:30 - 14:15)
Organised by: Logo
Congress Presentation Part of: Hypertrophic obstructive cardiomyopathy: treatment, monitoring, and outcomes Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

ESC 365 is supported by

ESC 365 is supported by